GlassScriptPhysician profile
Ibrahim Haddad
NPI 1164915690
$755.07
in general payments reported to CMS, 2019-2025
13 companies · $755 in 2025
The $755 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $755.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $216.07 | 2025 | Tezspire, Fasenra, Breztri |
| Merck Sharp & Dohme LLC | $163.59 | 2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $72.88 | 2025 | Dupixent |
| Glaxosmithkline, LLC. | $58.78 | 2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $49.86 | 2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $42.89 | 2025 | |
| Amgen INC. | $41.66 | 2025 | Tavneos, Tezspire |
| Actelion Pharmaceuticals US, INC. | $22.44 | 2025 | Opsumit, Opsynvi, Uptravi |
| Grifols USA, LLC | $18.80 | 2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.64 | 2025 | Ofev |
| Liquidia Technologies, INC. | $18.16 | 2025 | Yutrepia |
| Genzyme Corporation | $16.23 | 2025 | |
| Verona Pharma, INC. | $15.07 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.